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Abstract
Background: In response to the high financial burden of health services facing tuberculosis (TB) patients in China,
the China-Gates TB project, Phase II, has implemented a new financing and payment model as an important
component of the overall project in three cities in eastern, central and western China. The model focuses on
increasing the reimbursement rate for TB patients and reforming provider payment methods by replacing fee-for-
service with a case-based payment approach. This study investigated changes in out-of-pocket (OOP) health
expenditure and the financial burden on TB patients before and after the interventions, with a focus on potential
differential impacts on patients from different income groups.
Methods: Three sample counties in each of the three prefectures: Zhenjiang, Yichang and Hanzhong were chosen
as study sites. TB patients who started and completed treatment before, and during the intervention period, were
randomly sampled and surveyed at the baseline in 2013 and final evaluation in 2015 respectively. OOP health
expenditure and percentage of patients incurring catastrophic health expenditure (CHE) were calculated for
different income groups. OLS regression and logit regression were conducted to explore the intervention’s impacts
on patient OOP health expenditure and financial burden after adjusting for other covariates. Key-informant
interviews and focus group discussions were conducted to understand the reasons for any observed changes.
Results: Data from 738 (baseline) and 735 (evaluation) patients were available for analysis. Patient mean OOP
health expenditure increased from RMB 3576 to RMB 5791, and the percentage of patients incurring CHE also
increased after intervention. The percentage increase in OOP health expenditure and the likelihood of incurring
CHE were significantly lower for patients from the highest income group as compared to the lowest. Qualitative
findings indicated that increased use of health services not covered by the standard package of the model was
likely to have caused the increase in financial burden.
Conclusions: The implementation of the new financing and payment model did not protect patients, especially
those from the lowest income group, from financial difficulty, due partly to their increased use of health service.
More financial resources should be mobilized to increase financial protection, particularly for poor patients, while
cost containment strategies need to be developed and effectively implemented to improve the effective coverage
of essential healthcare in China.
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Background
China is among the countries with the highest burden of
tuberculosis (TB). According to the WHO Global Tu-
berculosis Report 2017, China ranked 3rd in terms of in-
cident TB cases and 2nd on multi-drug resistant TB
(MDR-TB) [1]. In order to achieve the health-related
Sustainable Development Goal (SDG) proposed by the
United Nations and end the TB epidemic by 2030,
standard medical treatment needs to be made accessible
and affordable for all TB patients [2].
Currently the TB service delivery system in China has
been undergoing a transformation whereby responsibil-
ity for provision of clinical services is being gradually
shifted from TB dispensaries to designated hospitals,
typically general hospitals or infectious disease hospitals,
in most of the provinces [3]. This transformation has had
considerable cost implications, as studies have shown that,
while quality of care has often been improved,
income-pursuing behaviors, such as over-prescription and
unnecessary hospitalization have driven up the treatment
cost of TB [4–7]. Previous studies also show that although
over 95% of the Chinese population is covered by the
three public health insurance systems – Urban Employee
Basic Medical Insurance (UEBMI), Urban Resident Basic
Medical Insurance (URBMI) and New Cooperative
Medical Schemes (NCMS) [8] – TB patients bear a high
economic burden for medical treatment, especially
low-income and rural patients [6, 9–12]. Financial factors
are also frequently mentioned as a major reason for
non-adherence to treatment, suspended treatment and
eventual non-cure [13–17]. As a majority of TB patients
live in poor households [18, 19], it seems likely that the fi-
nancial protection provided by the current health insur-
ance schemes is far from sufficient.
In response to the financial difficulties faced by pa-
tients, the China-Gates TB project, Phase II has imple-
mented a new financing and payment model as one
component of a set of interventions that aims at improv-
ing TB control in China. Before project implementation,
studies from the baseline survey have found that the
medical cost was relatively high in the project area [4].
The effect of NCMS on reducing catastrophic health ex-
penditure (CHE) for TB patients was very limited [9],
and the percentage of poor patients who incurred CHE
was much higher than the rich [20]. The new model fo-
cuses on improving the reimbursement rate for TB pa-
tients and introducing hospital payment reforms,
moving from a fee-for-service to a case-based payment
approach. A treatment guideline was also launched with
a standard service package, the cost of this being cov-
ered under the new model. Transportation and subsist-
ence allowances are also provided to patients who
adhere to treatment. The other components such as
establishing a comprehensive TB control model, are
documented elsewhere [12].
While increasing the reimbursement rate appears to
have obvious potential benefits for patients, the implica-
tions of the case-based payment approach are not clear.
By setting a fixed payment rate for each case, case-based
payment aims to reduce non-necessary medical services
by altering provider incentives. Diagnostic-related group
(DRG) case-based payment mechanisms, have been im-
plemented in numerous developed and developing coun-
tries, and in some cases have demonstrated effectiveness
in cost containment [21–23]. Previous studies in China
have found mixed results regarding the impact of
case-based payments in terms of reducing medical costs
for different types of disease, but little evidence of re-
duced overall inpatient expenditure [24–29]. In addition,
it has been found that the impact may be compromised
by problems that have arisen in project implementation,
for example with hospitals excluding patients whose
treatment cost is higher than the payment limit [25, 29].
For TB specifically, at least one study suggests that a
case-based payment approach with no co-payment for
patients may be feasible and beneficial under the NCMS
[30]. However, there is a lack of evidence as to the ef-
fects in terms of cost control and patient financial
burden of adopting a model combining increased reim-
bursement rates and case-based payment. In particular,
it remains unknown whether this approach could pro-
tect the most economically vulnerable groups from
financial difficulty.
At the end of the second phase of the China-Gates TB
project, a team led by Duke Global Health Institute car-
ried out an evaluation of the effects of the interventions
on equity in access to/use of TB services, and on changes
in financial protection for TB patients. This article aims to
investigate changes in the out-of-pocket (OOP) health ex-
penditure and financial burden of TB patients before and
after the implementation of the new model, while a com-
panion paper by Dong et al. which is published in the fol-
lowing issue considers changes in service utilization. It
also examines the equity implications of the new model
for patients from different socio-economic groups,
especially those living in poverty.
Methods
The study was conducted in Zhenjiang, Yichang and
Hanzhong, three prefectures located in eastern, central
and western China respectively. In each prefecture, three
sample counties at different levels of economic develop-
ment were selected, one economically disadvantaged and
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located in a remote area to ensure that we included a
substantial number of patients living in poverty. A
mixed-method approach, including a patient question-
naire survey and qualitative interviews, was used to in-
vestigate patients’ financial burden due to TB treatment.
The study design is shown in Fig. 1.
Data collection
Patient survey
The intervention period was from April 2014 to March
2015. The baseline survey was conducted in 2013 and
the final evaluation late in 2015, with 90 patients ran-
domly sampled from the list of registered TB patients in
each county for both surveys. The inclusion criterion for
the baseline required that patients had completed treat-
ment before the survey, and for the final evaluation that
patients started and completed treatment during the
intervention period. Face-to-face interviews were con-
ducted by trained investigators using a structured survey
questionnaire which collected basic demographic infor-
mation and data on socio-economic status, treatment
procedures and expenditures. All questionnaires were
checked on site for completeness and internal logic, and
they were captured for analysis using a double-entry
procedure in EpiData (http://www.epidata.dk/).
Qualitative interviews
Qualitative data were gathered during the evaluation of
the project and used to gain an understanding of stake-
holders’ perceptions of the effects of the new payment
model on financial protection for TB patients.
Semi-structured, in-depth interviews were conducted
with participants responsible for the development and
implementation of local policies, including officers of
the local health bureau and civil affair bureau, health in-
surance managers and hospital managers at city-level
and county-level, a total of 72 interviews across all study
sites. Focus group discussions (FGD) were also con-
ducted among care-givers (physicians and nurses, n = 11
in total) and TB patients who completed the 6-month
first-line treatment during the intervention period (n = 9
in total), with each group consisting of 5–6 participants.
Gender, household income, type of health insurance
coverage and distance from downtown were considered
to ensure diversity of participants in the patient FGDs.
The topic guides were developed and piloted before for-
mal interview. All qualitative interviews were conducted
by scholars with qualitative study experience. All inter-
views were conducted in a private room, and were re-




Out-of-pocket (OOP) health expenditure, calculated by
adding up direct health expenditures for all outpatient
and inpatient services, and the percentage of patients in-
curring CHE, defined as OOP health expenditure over
10% of annual household income or 40% of annual
non-food expenditure [20], were used to evaluate pa-
tients’ treatment expenses and financial burden before
and after the intervention. Chi-square tests were con-
ducted to examine if there were significant differences
between the baseline and final patient samples in terms
of demographic and socio-economic characteristics in-
cluding age, gender, insurance cover and household
income.
In order to explore the new model’s potential differen-
tial impact on patients from different income groups, es-
pecially the effect on the poorest patients that are most
susceptible to financial difficulty, patients were catego-
rized, based on the per capita income of their household,
as extremely poor (below the 1.9 USD per capita per day
defined by the World Bank, which equated to 4369
RMB per capita per year), moderately poor (1.9–5.5
USD per capita per day or 4369–12 647 RMB per capita
per year, defined by the World Bank as the poverty line
for middle and high income countries) and non-poor (≥
Fig. 1 Flow chart of the study design
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5.5 USD per capita per day or 12 647 RMB per capita
per year) [31]. T-tests were used to determine if there
were significant differences in OOP health expenditure
before and after the intervention for all patients and for
selected subgroups. Linear regression was used to model
the effect of the intervention on the natural logarithm of
OOP, and logistic regression to estimate the effect on
the percentage of patients incurring CHE. The regres-
sion models were estimated both for all patients and for
patients from different income groups, in both cases
using other demographic and socio-economic factors as
explanatory variables and controlling for county fixed ef-
fects. Crude and standardized (adjusting for age, gender
and patient category) concentration indices for OOP
health expenditure, were calculated to assess the degree
of equity across income groups in the financing of TB
treatment before and after the intervention [32]. The
quantitative data were analyzed using STATA 13.1(Stata-
Corp, Texas, USA).
Qualitative
The qualitative data were analyzed using the thematic
analysis approach [33]. The analysis framework was de-
veloped based on a topic guide and emerging themes
from the transcripts, and was refined during the coding
process. All qualitative data were coded, sorted and
classified according to the framework, and discussed
across the research team till reaching consensus. The
trustworthiness of data was enhanced by triangulating
findings from different respondents and methods. We
used the original Chinese texts for analysis, and
translated the quotations into English. The analysis
was conducted using NVIVO 9.0 (QSR International,
Melbourne, Australia).
Results
Characteristics of the patients surveyed
A total of 797 and 798 patients agreed to participate in
the baseline and evaluation surveys respectively, and 738
(baseline) and 735 (evaluation) reported their
out-of-pocket health expenditure and were included in
the analysis. Table 1 indicates that there were no signifi-
cant differences between the baseline and final samples
with respect to gender, age, employment, education and
household income. Most were male and new patients.
Around 50% were aged over 60, and 85% had never
completed high school. Half were not employed at the
time of the survey. Some 1/3 lived in households below
the poverty line and 24% were above the non-poor
threshold. Over 80% were covered by the NCMS, as
most lived in rural area. Overall, most are likely to come
from the low socio-economic group, as reflected by their
education and income status.
Out-of-pocket health expenditure
The mean OOP health expenditure was RMB 3576 (me-
dian 1752) before and RMB 5791 (median 2700) after
the implementation of the new financing model (Table 2).
The most significant increase (P < 0.001) was for the
poorest, whose mean OOP expenditure more than dou-
bled, while the moderately poor experienced an increase
of almost 70%. Only for patients in the highest income
group was the percentage increase relatively limited and
not statistically significant.
The overall degree of inequality in OOP payments also
increased, as is reflected by the positive value of the con-
centration index before and negative value after imple-
menting the new model (Table 3). This result remains
unchanged after adjusting for age, gender and patient
category (new or relapse patients). The concentration
curves are depicted in Fig. 2, which clearly shows that
the accumulated share of total OOP health expenditure
paid by poor patients was higher after the intervention,
as the curve for the intervention period always lies above
the baseline.
Financial burden
For the overall sample, the percentage of patients that
incurred CHE increased from 47.8 to 56.3% using the
10% of household income threshold (CHE_10), and from
32.4 to 36.5% using the 40% non-food expenditure
threshold (CHE_40) after implementation of the new
model, and the increase was statistically significant for
the former (Table 4). The financial burden of TB treat-
ment increased for both lower income groups (P < 0.05
for CHE_10). Only patients who were relatively well-off
experienced no significant change in either CHE index.
It is notable that the financial burden was extremely
high for the poorest patients, with over 82.5% of those
who lived below the poverty line spending more than
10% of their household income, and a majority spending
40% of their non-food expenditure, on medical services
after the intervention.
Factors associated with the financial burden of TB care
Table 5 shows the results of an OLS regression of the
logarithm of direct OOP health expenditure (model 1)
and logit regressions of CHE (model 2 and 3) on project
intervention, after adjusting for the covariates gender,
age, education, employment status, insurance cover and
controlling for county fixed effects. Results from the
OLS regression again clearly show that implementation
of the new model was associated with a significant in-
crease in OOP health expenditure. Results from the logit
regressions also reveal a significant increase in the per-
centage of patients incurring CHE after project imple-
mentation for both the 10% of household income and
40% of non-food expenditure thresholds.
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Table 2 Out-of-pocket health expenditure before and after intervention by income group (RMB)
Income group Before intervention After intervention % change P-value
Mean Median Mean Median Mean Median (Means)
< 4369 RMB 2876 1428 5961 2700 107.3 89.1 < 0.001
4369–12 647 RMB 3656 1752 6169 2780 68.7 58.7 0.002
> 12 647 RMB 4409 2400 4972 2570 12.8 7.1 0.4
Overall 3576 1752 5791 2700 61.9 54.1 < 0.001
Table 1 Characteristics of patient samples before and after intervention (%)
Before intervention (n = 738) After intervention (n = 735) P-value1
Gender
Male 555 (75.2%) 532 (72.4%) 0.218
Age
< 30 45 (6.1%) 58 (7.9%) 0.065
30–59 352 (47.7%) 309 (42.0%)
≥ 60 341 (46.2%) 468 (50.1%)
Marital status
Married 595 (80.6%) 575 (78.3%) 0.278
Patient category
new patient 594 (81.4%) 602 (81.9%) 0.791
Education level
None 140 (19.0%) 166 (22.7%) 0.119
Primary school 242 (32.8%) 247 (33.7%)
Secondary school 262 (33.5%) 221 (31.1%)
≥ high school 94 (12.7%) 99 (12.5%)
Insurance type
UEBMI 45 (6.1%) 69 (9.4%)
resident insurance 21 (2.8%) 45 (5.9%)
NCMS 648 (87.8%) 598 (81.6%) 0.000
other insurance 16 (2.2%) 5 (0.7%)
no insurance 8 (1.1%) 18 (2.5%)
Employment
Employed 403 (54.6%) 369 (50.2%) 0.0912
Unemployed 40 (5.4%) 55 (7.5%)
Retired 252 (34.2%) 86 (11.7%)
lost ability 35 (4.7%) 91 (12.4%)
other 8 (1.1%) 134 (18.2%)
Income groupa
< 4369 RMB 243 (33.2%) 240 (33.5%) 0.970
4369–12 647 RMB 314 (42.9%) 303 (42.3%)
> 12 647 RMB 175 (23.9%) 174 (23.2%)
UEBMI Urban Employee Basic Medical Insurance, NCMS New Cooperative Medical Schemes
1 P-value for chi-square test. 2 P-value for comparison employed vs unemployed
aThe numbers in the three categories do not add up to total due to missing data
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Differential influences of the model on the OOP health
expenditure and financial burden of patients from differ-
ent income groups are also observed, as is reflected by
the statistically significant coefficients for the interaction
term of the intervention period and the highest income
group for both models 1 and 3. The OOP health ex-
penditure of this group did not increase as much as that
for the poorest, and their financial burden remain rela-
tively unchanged. It is also notable that being covered by
UEBMI and NCMS is associated with lower OOP health
expenditure and reduced likelihood of incurring CHE.
The qualitative data revealed a variety of stakeholder
opinions as to the impact of the model, and provided in-
sights into factors contributing to the high OOP health
expenditure and financial burden following the interven-
tion. Policy makers (directors of local health and family
planning bureau and health insurance office) in the three
study sites generally thought that the new financing and
payment model would be beneficial for TB patients and
could effectively reduce their financial burden. On the
other hand, some directors of the insurance office admit-
ted that patients with serious comorbidities had been ex-
cluded from the intervention and thus their costs were
not subject to the cost limit set by the case-based
payment policy.
“The policies are good … the reimbursement increased
to 70% and patients financial burden are relieved …
…” (Director of Health and family planning bureau,
prefecture level)
“Many patients have comorbidities. Originally it was
stipulated that the hospitals bear the cost exceeding
the fixed rate. However, if the patients have serious
comorbidities, like chronic obstructive pulmonary
disease and hemoptysis, their treatment costs were
really high and sometimes they even need to be
transferred to Intensive Care Unit..We could not apply
case-based payment for these patients.” (Director of
health insurance office, prefecture level)
Focus group discussions with TB patients reinforced
the finding that patients still bear a considerable finan-
cial burden for treatment, especially those with comor-
bidities. Many patients said they took liver-protection
and other auxiliary drugs in addition to TB medication,
even though these drugs were not included in the stan-
dardized TB treatment package. These patients could
therefore not enjoy the higher reimbursement rates and
nor were the costs of the drugs restricted by the
case-based payment limit. In addition, the costs for pa-
tients who were transferred to higher level hospitals due
to their severe condition were also not covered by the
new model. In focus groups discussions with physicians
it was argued that the standard treatment package was
very limited, which meant that a number of the medical
services commonly used by the patients were not in-
cluded, especially for those with comorbidities. Some
physicians also conceded that their income levels were
correlated with the net revenue of the department,
mainly generated from service provision and drug sales.
“You have to take these liver-protection drugs, and
they cannot be reimbursed for us young people (with-
out special insurance).” (TB patient, FGD)
“I had hemoptysis and I was transferred to xxx
Hospital (prefecture-level TB designated hospital) from
the xx hospital (county-level hospital) … … I was
hospitalized for over a month. Then one month after
the discharging from the hospital my conditions
relapsed, and the doctors in xxx Hospital asked me to
go for more checks in xxxx Hospital (prefecture-level
general hospital) where I spent over 20 000 RMB …
…” (TB patient, FGD)
“The treatment of comorbidities are not included in
the new reimbursement policy … Patients’
complications typically happened when they were
readmitted into the hospital, and in this situation they
Table 3 Concentration index of out-of-pocket health
expenditure before and after intervention
Period Crude Standardized
Before intervention 0.0918 0.0878
After intervention −0.0262 −0.0049
Fig. 2 Concentration curve of out-of-pocket health expenditure
before and after intervention.
OOP: out-of-pocket
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Table 4 Percent of households incurring CHE before and after intervention by income group
Income group CHE_10/% CHE_40/%
Before intervention After intervention P-value Before intervention After intervention P-value
< 4369 RMB 72.8 82.3 0.016 43.0 52.0 0.055
4369–12 647 RMB 41.6 52.2 0.009 27.3 32.5 0.163
> 12 647 RMB 25.1 31.0 0.221 27.5 22.8 0.316
Overall 47.8 56.3 0.001 32.4 36.5 0.113
CHE_10: 10% of household income threshold; CHE_40: 40% non-food expenditure threshold
Table 5 Regression of the logarithm of out-of-pocket and logit regressions of catastrophic health expenditure on an intervention
dummy variable and other cofactors
Model 1: log OOP Model 2: CHE_10% Model3: CHE_40%
Coef. P > |t| Odds ratio P > |t| Odds ratio P > |t|
Intervention period
after intervention 0.572 0.013 1.86 0.033 1.50 0.021
Income group
< 4369 RMB ref. ref. ref.
4369–12 647 RMB 0.217 0.063 0.29 < 0.001 0.59 0.001
> 12 647 RMB 0.436 0.025 0.14 < 0.001 0.72 0.275
Period*income group
< 4369 RMB ref. ref. ref.
4369–12 647 RMB −0.144 0.280 0.81 0.451 0.87 0.286
> 12 647 RMB −0.426 0.046 0.71 0.168 0.52 0.001
Gender
Male 0.03 0.743 1.12 0.424 1.13 0.382
Age
30–59 −0.047 0.868 1.13 0.702 1.47 0.374
≥ 60 0.188 0.454 1.61 0.121 2.90 0.022
Patient category
Relapse −0.011 0.911 0.97 0.873 0.87 0.275
Marriage
Married 0.176 0.004 0.94 0.629 1.01 0.928
Education
No education ref. ref. ref.
Primary 0.08 0.410 1.13 0.506 1.42 0.087
Secondary 0.256 0.006 1.26 0.141 1.05 0.800
≥ high school 0.312 0.130 1.32 0.287 1.46 0.014
Insurance type
Other ref. ref. ref.
UEMBI −0.492 0.009 0.41 < 0.001 0.42 0.004
NCMS −0.441 0.005 0.64 0.016 1.06 0.824
Employment
Working −0.246 0.022 0.71 0.002 0.70 < 0.001
CHE_10: 10% of household income threshold; CHE_40: 40% non-food expenditure threshold
UEBMI Urban Employee Basic Medical Insurance, NCMS New Cooperative Medical Schemes. Coef. Coefficient, OOP Out-of-pocket
Period*income group: the interaction terms of period (after intervention) and three income groups
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could not enjoy the new policy either.” (TB physician,
county-level, FGD)
(Our income) is correlated with the net income of the
department. He (the hospital manager) set a line ….
For example, you treat 100 patients and bring in such
an income, and how much you can take from the
income … (TB physician, prefecture-level, FGD)
Discussion
This study shows that the average OOP health expend-
iture and financial burden on the patients increased after
implementing the new financing and payment mode.
National statistics show that the average outpatient cost
per visit increased 13.3% and average inpatient cost per
admission increased 11.1% over the intervention period.
Clearly, the percentage increase following the interven-
tion was much higher and cannot be fully explained by
the general rising trend in healthcare costs [34]. As evi-
denced in the companion paper by Dong et al., the new
model contributed to a substantially increased use of
outpatient and inpatient services, especially for the low-
est income group. Their hospitalization rate increased
from 48.5 to 70.7%, and the number of outpatient visits
from 4.6 to 5.7. From an equity prospective, the reduced
differences in service use across different income groups
can be seen as a positive outcome of the intervention. No
one would wish to see poorer patients avoiding CHE by
choosing not to access the services they need. Neverthe-
less, the intervention also resulted in an increased inequal-
ity in OOP payments for TB care. Clearly the model did
not provide sufficient financial protection to offset the
substantially increased costs resulting partly from the in-
crease access promoted by the intervention, and both the
project designers and implementers at the national and
local levels may not have fully anticipated this situation.
Qualitative results from the study offer several possible
reasons why poorer patients paid more out-of-pocket
during the intervention period. While the new model
encouraged poor patients to start and adhere to regular
treatment, many of the medical services they received
were not included in the standard treatment package,
and were thus not reimbursed at a higher rate. The costs
of these medical services were also not restricted by the
case-based payment limit as defined by the project pol-
icies. Studies have shown that patients in lower
socio-economic status tend to delay treatment [35], and
thus they are more likely to result in more treatments
for complications or comorbidities eventually, thus in-
creasing out-of-pocket payments for services not cov-
ered by the model. Moreover, if their condition was
severe, they risked being excluded from the project be-
cause physicians in these designated hospitals were
concerned that their department/unit would have to
incur a deficit if the treatments they provide to the pa-
tients with serious co-morbidities are paid for using the
case-based payment. Alternatively, they might be trans-
ferred to higher level hospitals where they would not
enjoy the benefits of the new policies. From the phys-
ician side, as their incomes are closely related to the net
income of the department, they had an incentive to ex-
clude patients with severe comorbidities from the
program, or prescribe medical services outside the treat-
ment package to increase revenue.
In light of the financial difficulty faced by the poor pa-
tients, future policies concerning the financing of TB
treatment might need to consider a strategy that is more
supportive. A systematic review on interventions to re-
duce illness and injury related financial burden shows
that eliminating or largely reducing copayments in
current insurance schemes is effective in reducing OOP
medical payments [36]. Evidence from cash transfer pro-
grams to support TB households in low and middle in-
come countries also shows that this strategy could
increase the TB cure rate [37], and one study in Peru
also finds a reduction in CHE [38]. Based on this inter-
national experience and findings from our study, im-
proving the reimbursement rate for all TB related
medical services is necessary to reduce poor TB patients’
financial burden. However, it is also critical to ensure that
the costs of all these medical services are restricted by the
case-based payment; otherwise there remains an incentive
for physicians to pursue income by prescribing unneces-
sary drugs and treatments. In addition, more financial re-
sources, for example earmarked funds from government,
should be mobilized to subsidize poor patients, especially
those with complications and comorbidities.
This study has several limitations. One major limita-
tion is that we did not have a formal list of patients who
were included in the program throughout their treat-
ment and those who were excluded. Nevertheless, as the
new model was required by the government to be imple-
mented in all designated hospitals, it would seem likely
that the vast majority of patients were included. It can
also be argued that assessment of the model under the
current health system implies that its effectiveness may
have been influenced by implementation barriers known
to be imbedded in that system, for example the ten-
dency for hospitals to avoid innovations that they per-
ceive as potential threats to income generation. We
did not ask about complications and comorbidities in
the survey, and we cannot exclude the possibility that
the patients enrolled in treatment during the project
had more severe conditions and incurred higher costs
for this reason. In addition, recall bias is likely as we
asked patients about the whole treatment period since
the onset of symptoms.
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Conclusions
The mean out-of-pocket health expenditure and finan-
cial burden of TB patients increased after the implemen-
tation of the new model and we would argue that the
limitations mentioned above did not substantially influ-
ence this conclusion, given the degree of the observed
increase. Apparently, the new financing and payment
model was not successful in protecting poor patients
from financial difficulty during their treatment. Future
research may be required to look into strategies to pro-
vide more financial protection for poorer patients and
impose effective cost control.
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